Amneal Pharmaceuticals Inc (FRA:2DT)
€ 7.7 0 (0%) Market Cap: 2.45 Bil Enterprise Value: 4.93 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 62/100

Q2 2024 Amneal Pharmaceuticals Inc Earnings Call Transcript

Aug 09, 2024 / 12:30PM GMT
Release Date Price: €6.7 (+7.20%)

Key Points

Positve
  • Amneal Pharmaceuticals Inc (AMRX) reported strong Q2 results with a 17% revenue growth across all business segments.
  • The company raised its 2024 guidance, expecting net revenue between $2.7 billion and $2.8 billion, reflecting 13% to 17% year-over-year growth.
  • The recent US FDA approval of CREXONT for Parkinson's disease is a significant milestone, with expected US peak sales of $300 million to $500 million.
  • Amneal's biosimilar segment is on track for over $125 million in revenue in 2024, with five additional pipeline products expected to launch between 2025 to 2027.
  • The AvKARE distribution business has more than doubled since acquisition in 2020, with expected revenue of over $675 million in 2025.
Negative
  • The company's adjusted EPS of $0.16 declined by $0.03 due to interest expense and higher sales outstanding.
  • Despite strong revenue growth, the overall adjusted EBITDA growth was only 11%, indicating potential margin pressures.
  • The launch of the DHE auto-injector for migraine and cluster headache has been delayed to the second quarter of next year.
  • Amneal's net leverage remains relatively high at 4.4 times, although it has decreased from previous years.
  • The generic pricing environment, although improved, remains challenging, with past years marked by unsustainable pricing pressures.
Operator

Good morning and welcome to the Amneal Pharmaceuticals second quarter 2024 earnings call. I'd now like to turn the call over to Amneal's Head of Investor Relations, Tony DiMeo.

Tony DiMeo
Amneal Pharmaceuticals Inc - Head of IR

Good morning and thank you for joining Amneal Pharmaceuticals second quarter 2024 earnings call. Today, we issued a press release reporting Q2 results. The earnings press release and presentation are available at amneal.com.

Certain statements made on this call regarding matters that are not historical facts, including but not limited to, management's outlook or predictions, are forward-looking statements that are based solely on information that is now available to us.

Please see the section entitled Cautionary Statements on Forward-Looking Statements for factors that may impact future performance. We also discuss non-GAAP measures. Information on use of these measures and reconciliations to GAAP are in the earnings release and presentation.

On the call today are Chirag and Chintu Patel, Co-Founders and Co

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot